BAY CITY CAPITAL LLC
CIK 1288452 · last filed 2021-10-26
BAY CITY CAPITAL LLC is a corporate insider who has filed 23 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing, for XLO, was dated Oct 26, 2021. Across all open-market trades the lifetime net is −$489.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $84.5M across reported positions. The firm reports its address in San Francisco, CA. 34 SEC filings were submitted jointly with Bay City Capital Fund V Co-Investment Fund, L.P.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$84.50M
12
23
-$489.64M
Filer Profile
SAN FRANCISCO, CA 94111
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XLO | 10%+ Owner | 58,356 | $9.00 | $525.2K | $5.00M | 1 | 2021-10-26 |
| MDGL | Director | 154,255 | $541.08 | $83.46M | -$586.74M | 3 | 2020-05-29 |
| Enliven Therapeutics, Inc. (IMRA) Delisted | 10%+ Owner | 175,845 | $14.59 | $2.57M | $0 | 1 | 2020-03-16 |
| Kezar Life Sciences, Inc. (KZR) Delisted | 10%+ Owner | 62,223 | $7.29 | $453.6K | $2.25M | 1 | 2018-06-28 |
| Viracta Therapeutics, Inc. (SNSS) Delisted | 10%+ Owner | 3,013,966 | $18.62 | $56.12M | -$2.34M | 4 | 2015-07-28 |
| NEVRO CORP (NVRO) Delisted | 42,658 | $5.84 | $249.1K | $0 | 1 | 2014-11-12 | |
| DERM | Director | 65,572 | $7.86 | $515.4K | $4.42M | 1 | 2014-10-08 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | 10%+ Owner | 2,221,067 | — | — | $0 | 3 | 2013-07-19 |
| Epizyme, Inc. (EPZM) Delisted | 10%+ Owner | 3,492,063 | $1.47 | $5.13M | $10.00M | 1 | 2013-06-07 |
| ReShape Weightloss Inc. (ETRM) Delisted | 10%+ Owner | 51,451 | — | — | $11.83M | 3 | 2010-12-16 |
| VIA Pharmaceuticals, Inc. (VIAP) Delisted | 10%+ Owner | 219,284 | — | — | $39.52M | 2 | 2007-08-08 |
| PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted | 10%+ Owner | 4,383,684 | — | — | $26.42M | 1 | 2007-04-30 |
Recent Filings
23 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-10-26 | XLO | Mixed | +1,129,490 | $5.00M | EDGAR |
| 2020-05-29 | MDGL | Other (J) | −1,648,944 | $0 | EDGAR |
| 2020-03-16 | Enliven Therapeutics, Inc. (IMRA) Delisted | Mixed | +2,813,520 | $0 | EDGAR |
| 2019-12-13 | MDGL | Sell (S) | −4,800,000 | -$506.26M | EDGAR |
| 2018-06-28 | Kezar Life Sciences, Inc. (KZR) Delisted | Mixed | +622,229 | $2.25M | EDGAR |
| 2018-06-12 | MDGL | Sell (S) | −280,000 | -$80.49M | EDGAR |
| 2016-08-02 | — | Buy (P) | +120,724,344 | $12.00M | |
| 2015-07-28 | Viracta Therapeutics, Inc. (SNSS) Delisted | Mixed | +4,120,512 | -$2.5K | EDGAR |
| 2014-11-12 | NEVRO CORP (NVRO) Delisted | Conv (C) | +8,773,028 | $0 | EDGAR |
| 2014-10-08 | DERM | Mixed | +13,957,628 | $4.42M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.